Abstract

Although polymeric nanoconjugates (NCs) hold great promise for the treatment of cancer patients, their clinical utility has been hindered by the lack of efficient delivery of therapeutics to targeted tumor sites. Here, we describe an albumin-functionalized polymeric NC (Alb-NC) capable of crossing the endothelium barrier through a caveolae-mediated transcytosis pathway to better target cancer. The Alb-NC is prepared by nanoprecipitation of doxorubicin (Doxo) conjugates of poly(phenyl O-carboxyanhydrides) bearing aromatic albumin-binding domains followed by subsequent surface decoration of albumin. The administration of Alb-NCs into mice bearing MCF-7 human breast cancer xenografts with limited tumor vascular permeability resulted in markedly increased tumor accumulation and anti-tumor efficacy compared to their conventional counterpart PEGylated NCs (PEG-NCs). The Alb-NC provides a simple, low-cost and broadly applicable strategy to improve the cancer targeting efficiency and therapeutic effectiveness of polymeric nanomedicine.

Original languageEnglish (US)
Pages (from-to)1189-1200
Number of pages12
JournalBiomaterials Science
Volume6
Issue number5
DOIs
StatePublished - May 2018

Fingerprint

Nanoconjugates
Tumors
Albumins
Bearings (structural)
Medical nanotechnology
Heterografts
Doxorubicin
Costs

ASJC Scopus subject areas

  • Biomedical Engineering
  • Materials Science(all)

Cite this

Albumin as a "trojan Horse" for polymeric nanoconjugate transendothelial transport across tumor vasculatures for improved cancer targeting. / Yin, Qian; Tang, Li; Cai, Kaimin; Yang, Xujuan; Yin, Lichen; Zhang, Yanfeng; Dobrucki, Lawrence W.; Helferich, William G.; Fan, Timothy M.; Cheng, Jianjun.

In: Biomaterials Science, Vol. 6, No. 5, 05.2018, p. 1189-1200.

Research output: Contribution to journalArticle

@article{7aea5af09c964a729aee4ced49d6a61c,
title = "Albumin as a {"}trojan Horse{"} for polymeric nanoconjugate transendothelial transport across tumor vasculatures for improved cancer targeting",
abstract = "Although polymeric nanoconjugates (NCs) hold great promise for the treatment of cancer patients, their clinical utility has been hindered by the lack of efficient delivery of therapeutics to targeted tumor sites. Here, we describe an albumin-functionalized polymeric NC (Alb-NC) capable of crossing the endothelium barrier through a caveolae-mediated transcytosis pathway to better target cancer. The Alb-NC is prepared by nanoprecipitation of doxorubicin (Doxo) conjugates of poly(phenyl O-carboxyanhydrides) bearing aromatic albumin-binding domains followed by subsequent surface decoration of albumin. The administration of Alb-NCs into mice bearing MCF-7 human breast cancer xenografts with limited tumor vascular permeability resulted in markedly increased tumor accumulation and anti-tumor efficacy compared to their conventional counterpart PEGylated NCs (PEG-NCs). The Alb-NC provides a simple, low-cost and broadly applicable strategy to improve the cancer targeting efficiency and therapeutic effectiveness of polymeric nanomedicine.",
author = "Qian Yin and Li Tang and Kaimin Cai and Xujuan Yang and Lichen Yin and Yanfeng Zhang and Dobrucki, {Lawrence W.} and Helferich, {William G.} and Fan, {Timothy M.} and Jianjun Cheng",
year = "2018",
month = "5",
doi = "10.1039/c8bm00149a",
language = "English (US)",
volume = "6",
pages = "1189--1200",
journal = "Biomaterials Science",
issn = "2047-4830",
publisher = "Royal Society of Chemistry",
number = "5",

}

TY - JOUR

T1 - Albumin as a "trojan Horse" for polymeric nanoconjugate transendothelial transport across tumor vasculatures for improved cancer targeting

AU - Yin, Qian

AU - Tang, Li

AU - Cai, Kaimin

AU - Yang, Xujuan

AU - Yin, Lichen

AU - Zhang, Yanfeng

AU - Dobrucki, Lawrence W.

AU - Helferich, William G.

AU - Fan, Timothy M.

AU - Cheng, Jianjun

PY - 2018/5

Y1 - 2018/5

N2 - Although polymeric nanoconjugates (NCs) hold great promise for the treatment of cancer patients, their clinical utility has been hindered by the lack of efficient delivery of therapeutics to targeted tumor sites. Here, we describe an albumin-functionalized polymeric NC (Alb-NC) capable of crossing the endothelium barrier through a caveolae-mediated transcytosis pathway to better target cancer. The Alb-NC is prepared by nanoprecipitation of doxorubicin (Doxo) conjugates of poly(phenyl O-carboxyanhydrides) bearing aromatic albumin-binding domains followed by subsequent surface decoration of albumin. The administration of Alb-NCs into mice bearing MCF-7 human breast cancer xenografts with limited tumor vascular permeability resulted in markedly increased tumor accumulation and anti-tumor efficacy compared to their conventional counterpart PEGylated NCs (PEG-NCs). The Alb-NC provides a simple, low-cost and broadly applicable strategy to improve the cancer targeting efficiency and therapeutic effectiveness of polymeric nanomedicine.

AB - Although polymeric nanoconjugates (NCs) hold great promise for the treatment of cancer patients, their clinical utility has been hindered by the lack of efficient delivery of therapeutics to targeted tumor sites. Here, we describe an albumin-functionalized polymeric NC (Alb-NC) capable of crossing the endothelium barrier through a caveolae-mediated transcytosis pathway to better target cancer. The Alb-NC is prepared by nanoprecipitation of doxorubicin (Doxo) conjugates of poly(phenyl O-carboxyanhydrides) bearing aromatic albumin-binding domains followed by subsequent surface decoration of albumin. The administration of Alb-NCs into mice bearing MCF-7 human breast cancer xenografts with limited tumor vascular permeability resulted in markedly increased tumor accumulation and anti-tumor efficacy compared to their conventional counterpart PEGylated NCs (PEG-NCs). The Alb-NC provides a simple, low-cost and broadly applicable strategy to improve the cancer targeting efficiency and therapeutic effectiveness of polymeric nanomedicine.

UR - http://www.scopus.com/inward/record.url?scp=85046296256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046296256&partnerID=8YFLogxK

U2 - 10.1039/c8bm00149a

DO - 10.1039/c8bm00149a

M3 - Article

C2 - 29570190

AN - SCOPUS:85046296256

VL - 6

SP - 1189

EP - 1200

JO - Biomaterials Science

JF - Biomaterials Science

SN - 2047-4830

IS - 5

ER -